Reumatologia Pediátrica

Estudo randomizado | Secuquinumabe na artrite relacionada a entesite e na artrite psoriática juvenil.

16 Ago, 2022 | 12:47h

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial – Annals of Rheumatic Diseases

Estudo de coorte | Associação entre doenças autoimunes maternas e risco de transtornos mentais nos descendentes na Dinamarca.

21 Abr, 2022 | 12:05h

Association of Maternal Autoimmune Diseases With Risk of Mental Disorders in Offspring in Denmark – JAMA Network Open

Comentário no Twitter

https://twitter.com/JAMANetworkOpen/status/1515057370715594753

Estudo randomizado | Eficácia e segurança de longo prazo de ixekizumabe por até 108 semanas em pacientes pediátricos com psoríase moderada a grave.

19 Abr, 2022 | 12:16h

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial – JAMA Dermatology

Estudo original: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) – British Journal of Dermatology

Comentário no Twitter

In this RCT, by 108 weeks of use of ixekizumab for pediatric psoriasis, PASI 75/90/100 were achieved in 92%/79%/55%, respectively, of children, with clearance of nails in 68%, scalp in 76%, genital lesions in 88%, and palm/sole involvement in 90%. https://t.co/vk73Z3MKi4

— JAMA Dermatology (@JAMADerm) April 13, 2022

Estudo de coorte | Preditores de doença grave em crianças com síndrome inflamatória multissistêmica após infecção pelo SARS-CoV-2.

14 Abr, 2022 | 16:58h

Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study – Canadian Medical Association Journal

Comunicado de imprensa: Children older than 5 at higher risk of COVID-19-related multisystem inflammatory syndrome – Canadian Medical Association Journal

Comentário: Older Kids More Vulnerable to MIS-C: Study – HealthDay

Revisão de diretrizes nacionais | Fase aguda da doença de Kawasaki.

14 Abr, 2022 | 16:31h

Acute phase of Kawasaki disease: a review of national guideline recommendations – European Journal of Pediatrics

Revisão sistemática | Epidemiologia de manifestações musculoesqueléticas na doença inflamatória intestinal pediátrica.

8 Abr, 2022 | 21:21h

Epidemiology of Musculoskeletal Manifestations in Pediatric Inflammatory Bowel Disease: A Systematic Review – ACR Open Rheumatology

Diretriz BSR para tratamento de pacientes pediátricos, adolescentes e adultos com miopatia inflamatória idiopática.

5 Abr, 2022 | 12:04h

British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy – Rheumatology

Metanálise de 56 estudos randomizados controlados | Intervenções farmacológicas para doença de Kawasaki em crianças.

1 Abr, 2022 | 12:59h

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials – eBioMedicine

Comentário: Network meta-analysis rates treatments for Kawasaki disease – medwire News

Diretriz | Tratamento da dor nas costas inespecífica em crianças e adolescentes.

29 Mar, 2022 | 14:57h

Treatment of Unspecific Back Pain in Children and Adolescents: Results of an Evidence-Based Interdisciplinary Guideline – Children

Diretriz da ACR/Vasculitis Foundation para o tratamento da doença de Kawasaki.

9 Mar, 2022 | 13:53h

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease